The latest price target for Roivant Sciences (NASDAQ:ROIV) was reported by HC Wainwright & Co. on November 13, 2024. The analyst firm set a price target for $18.00 expecting ROIV to rise to within 12 months (a possible 53.71% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Roivant Sciences (NASDAQ:ROIV) was provided by HC Wainwright & Co., and Roivant Sciences reiterated their buy rating.

There is no last upgrade for Roivant Sciences

There is no last downgrade for Roivant Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Roivant Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Roivant Sciences was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Roivant Sciences (ROIV) rating was a reiterated with a price target of $18.00 to $18.00. The current price Roivant Sciences (ROIV) is trading at is $11.71, which is out of the analyst’s predicted range.